Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin A studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin AVitamin A (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Effect of vitamin A supplementation on the outcome severity of COVID-19 in hospitalized patients: A pilot randomized clinical trial

Somi et al., Nutrition and Health, doi:10.1177/02601060221129144, IRCT20170117032004N3
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -50% Improvement Relative Risk Ventilation 0% ICU admission 25% Time to clinical response -76% Hospitalization time -8% Vitamin A  Somi et al.  LATE TREATMENT  RCT Is late treatment with vitamin A beneficial for COVID-19? RCT 30 patients in Iran (April - July 2020) Trial underpowered for serious outcomes c19early.org Somi et al., Nutrition and Health, Oct 2022 Favorsvitamin A Favorscontrol 0 0.5 1 1.5 2+
Vitamin A for COVID-19
42nd treatment shown to reduce risk in June 2023, now with p = 0.021 from 14 studies.
Lower risk for recovery and cases.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 109 treatments. c19early.org
RCT 30 hospitalized patients in Iran, showing no significant difference with vitamin A treatment. All patients received HCQ. 50,000 IU/day intramuscular vitamin A for up to 2 weeks.
risk of death, 50.0% higher, RR 1.50, p = 1.00, treatment 3 of 15 (20.0%), control 2 of 15 (13.3%).
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 3 of 15 (20.0%), control 3 of 15 (20.0%).
risk of ICU admission, 25.0% lower, RR 0.75, p = 1.00, treatment 3 of 15 (20.0%), control 4 of 15 (26.7%), NNT 15.
time to clinical response, 76.0% higher, HR 1.76, p = 0.21, treatment 15, control 15, Kaplan–Meier.
hospitalization time, 8.1% higher, relative time 1.08, p = 0.49, treatment mean 7.33 (±2.31) n=15, control mean 6.78 (±1.84) n=15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Somi et al., 7 Oct 2022, Randomized Controlled Trial, Iran, peer-reviewed, mean age 60.2, 7 authors, study period April 2020 - July 2020, trial IRCT20170117032004N3. Contact: znikniaz@hotmail.com.
This PaperVitamin AAll
Effect of vitamin A supplementation on the outcome severity of COVID-19 in hospitalized patients: A pilot randomized clinical trial
Mohammad Hossein Somi, Masood Faghih Dinevari, Ali Taghizadieh, Mojtaba Varshochi, Elham Sadeghi Majd, Samaneh Abbasian, Zeinab Nikniaz
Nutrition and Health, doi:10.1177/02601060221129144
Introduction: Vitamin A is one of the vitamins that is suggested as adjuvant therapy in viral infections due to its immune enhancing role. In the present clinical trial, we intended to assess the effect of vitamin A supplementation on Coronavirus disease-2019 (COVID-19) in hospitalized patients. Methods: The present pilot randomized controlled clinical trial was conducted on 30 hospitalized patients with COVID-19. Patients in the intervention group received 50000 IU/day intramuscular vitamin A for a maximum of two weeks. Patients in the control group continued their common treatment protocols. All participants were followed up until discharge from the hospital or death. The primary outcome of the study was time to achieve clinical response based on the six classes of an ordinal scale. Time to clinical response was calculated based on the days needed to improve two scores on the scale or patient's discharge. Results: The time to clinical response was not significantly different between the two groups (7.23 ± 2.14 vs. 6.75 ± 1.85 days, respectively, p = 0.48). There was no significant difference between the groups regarding clinical response (hazard ratio: 1.76 [95% CI: 0.73, 4.26]). There were no significant differences between groups regarding the need for mechanical ventilation, duration of hospitalization, or death in the hospital. Conclusion: The results of this pilot clinical trial showed no benefit of vitamin A compared with the common treatment on outcome severity in hospitalized patients with COVID-19. Although the results are negative, there is still a great need for future clinical studies to provide a higher level of evidence.
Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Ethics approval and consent to participate This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving research study participants were approved by the Ethics Committee of Tabriz University of Medical Sciences (Ethics code: IR.TBZMED.REC.1398.1305). Written informed consent was obtained from all participants. In addition, the protocol of the trial was registered in IRCT (IRCT20170117032004N3).
References
Carr, A new clinical trial to test high-dose vitamin C in patients with COVID-19, Critical Care
Cucinotta, Vanelli, WHO Declares COVID-19 a pandemic, Acta bio-medica: Atenei Parmensis
Esakandari, Nabi-Afjadi, Fakkari-Afjadi, A comprehensive review of COVID-19 characteristics, Biological Procedures Online
Fawzi, Mbise, Fataki, Vitamin A supplementation and severity of pneumonia in children admitted to the hospital in Dar es Salaam, Tanzania, The American Journal of Clinical Nutrition
Grotto, Mimouni, Gdalevich, Vitamin A supplementation and childhood morbidity from diarrhea and respiratory infections: A meta-analysis, The Journal of Pediatrics
Iddir, Brito, Dingeo, Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: Considerations during the COVID-19 crisis, Nutrients
Li, Wu, Li, Revealing the targets and mechanisms of vitamin A in the treatment of COVID-19, Aging
Madatuwa, Mahawithanage, Chandrika, Evaluation of the effectiveness of the national vitamin A supplementation programme among school children in Sri Lanka, British Journal of Nutrition
Martins-Filho, Tavares, Vs, Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data, European Journal Of Internal Medicine
Nacul, Arthur, Kirkwood, The impact of vitamin A supplementation given during a pneumonia episode on the subsequent morbidity of children, Tropical Medicine & International Health
Peterson, Vock, Powers, Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization, Clinical Trials
Rodríguez, Hamer, Rivera, Effects of moderate doses of vitamin A as an adjunct to the treatment of pneumonia in underweight and normal-weight children: A randomized, double-blind, placebo-controlled trial, The American Journal Of Clinical Nutrition
Said, Mousa, Fawzi, Combined effect of high-dose vitamin A, vitamin E supplementation, and zinc on adult patients with diabetes: A randomized trial, Journal of Advanced Research
Si, Grytter, Vy, High dose vitamin A supplementation in the course of pneumonia in Vietnamese children, Acta Paediatrica
Soekarjo, Sd, Kusin, Effectiveness of weekly vitamin A (10,000 IU) and iron (60 mg) supplementation for adolescent boys and girls through schools in rural and urban east Java, Indonesia, European Journal of Clinical Nutrition
Sommer, Rahmathullah, Underwood, Potential interventions for the prevention of childhood pneumonia in developing countries: A meta-analysis of data from field trials to assess the impact of vitamin A supplementation on pneumonia morbidity and mortality. The vitamin A and pneumonia working group, Bulletin of the World Health Organization
Stephensen, Vitamin A, infection, and immune function, Annual Review Of Nutrition
Whitehead, Julious, Cooper, Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable, Statistical Methods In Medical Research
Wu, Ni, Wei, Vitamin A for non-measles pneumonia in children, Cochrane Database of Systematic Reviews
Zhang, Niu, ACE2 and COVID-19 and the resulting ARDS, Postgraduate Medical Journal
Zhou, Zuo, Li, Effects of nutrition intervention on the nutritional status and outcomes of pediatric patients with pneumonia, Minerva Pediatrica
{ 'indexed': {'date-parts': [[2022, 10, 7]], 'date-time': '2022-10-07T08:44:55Z', 'timestamp': 1665132295663}, 'reference-count': 22, 'publisher': 'SAGE Publications', 'license': [ { 'start': { 'date-parts': [[2022, 10, 7]], 'date-time': '2022-10-07T00:00:00Z', 'timestamp': 1665100800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'http://journals.sagepub.com/page/policies/text-and-data-mining-license'}], 'funder': [ { 'name': 'Liver and gastrointestinal diseases research center, Tabriz University of Medical ' 'Sciences, Tabriz, Iran'}], 'content-domain': {'domain': ['journals.sagepub.com'], 'crossmark-restriction': True}, 'abstract': '<jats:sec><jats:title>Introduction</jats:title><jats:p> Vitamin A is one of the vitamins that ' 'is suggested as adjuvant therapy in viral infections due to its immune enhancing role. In the ' 'present clinical trial, we intended to assess the effect of vitamin A supplementation on ' 'Coronavirus disease-2019 (COVID-19) in hospitalized patients. ' '</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> The present pilot ' 'randomized controlled clinical trial was conducted on 30 hospitalized patients with COVID-19. ' 'Patients in the intervention group received 50000 IU/day intramuscular vitamin A for a ' 'maximum of two weeks. Patients in the control group continued their common treatment ' 'protocols. All participants were followed up until discharge from the hospital or death. The ' 'primary outcome of the study was time to achieve clinical response based on the six classes ' 'of an ordinal scale. Time to clinical response was calculated based on the days needed to ' "improve two scores on the scale or patient's discharge. " '</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> The time to clinical ' 'response was not significantly different between the two groups (7.23\u2009±\u20092.14 vs. ' '6.75\u2009±\u20091.85 days, respectively, p\u2009=\u20090.48). There was no significant ' 'difference between the groups regarding clinical response (hazard ratio: 1.76 [95% CI: 0.73, ' '4.26]). There were no significant differences between groups regarding the need for ' 'mechanical ventilation, duration of hospitalization, or death in the hospital. ' '</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> The results of this ' 'pilot clinical trial showed no benefit of vitamin A compared with the common treatment on ' 'outcome severity in hospitalized patients with COVID-19. Although the results are negative, ' 'there is still a great need for future clinical studies to provide a higher level of ' 'evidence. </jats:p></jats:sec>', 'DOI': '10.1177/02601060221129144', 'type': 'journal-article', 'created': {'date-parts': [[2022, 10, 7]], 'date-time': '2022-10-07T08:23:26Z', 'timestamp': 1665131006000}, 'page': '026010602211291', 'update-policy': 'http://dx.doi.org/10.1177/sage-journals-update-policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Effect of vitamin A supplementation on the outcome severity of COVID-19 in hospitalized ' 'patients: A pilot randomized clinical trial', 'prefix': '10.1177', 'author': [ { 'given': 'Mohammad Hossein', 'family': 'Somi', 'sequence': 'first', 'affiliation': [ { 'name': 'Gastroenterologist, Liver and gastrointestinal diseases research ' 'center, Tabriz University of Medical Sciences, Tabriz, Iran'}]}, { 'given': 'Masood', 'family': 'Faghih Dinevari', 'sequence': 'additional', 'affiliation': [ { 'name': 'Gastroenterologist, Liver and gastrointestinal diseases research ' 'center, Tabriz University of Medical Sciences, Tabriz, Iran'}]}, { 'given': 'Ali', 'family': 'Taghizadieh', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pulmonologist, Tuberculosis and Lung Disease Research Center, ' 'Tabriz University of Medical Sciences, Tabriz, Iran'}]}, { 'given': 'Mojtaba', 'family': 'Varshochi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious disease specialist, Infectious and Tropical Diseases ' 'Research Center, Tabriz University of Medical Sciences, Tabriz, ' 'Iran'}]}, { 'given': 'Elham', 'family': 'Sadeghi Majd', 'sequence': 'additional', 'affiliation': [ { 'name': 'Student Research Committee, Tabriz University of Medical ' 'Sciences, Tabriz, Iran'}]}, { 'given': 'Samaneh', 'family': 'Abbasian', 'sequence': 'additional', 'affiliation': [ { 'name': 'Internist, Liver and gastrointestinal diseases research center, ' 'Tabriz University of Medical Sciences, Tabriz, Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-6522-1048', 'authenticated-orcid': False, 'given': 'Zeinab', 'family': 'Nikniaz', 'sequence': 'additional', 'affiliation': [ { 'name': 'Gastroenterologist, Liver and gastrointestinal diseases research ' 'center, Tabriz University of Medical Sciences, Tabriz, Iran'}]}], 'member': '179', 'published-online': {'date-parts': [[2022, 10, 7]]}, 'reference': [ { 'key': 'bibr1-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13054-020-02851-4'}, { 'key': 'bibr2-02601060221129144', 'first-page': '157', 'volume': '91', 'author': 'Cucinotta D', 'year': '2020', 'journal-title': 'Acta bio-medica: Atenei Parmensis'}, { 'key': 'bibr3-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12575-020-00128-2'}, { 'key': 'bibr4-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ajcn/68.1.187'}, { 'key': 'bibr5-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1067/mpd.2003.116'}, { 'key': 'bibr6-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/nu12061562'}, { 'key': 'bibr7-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.18632/aging.103888'}, { 'key': 'bibr8-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1017/S0007114507191923'}, { 'key': 'bibr9-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejim.2020.04.043'}, { 'key': 'bibr10-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1046/j.1365-3156.1998.00259.x'}, { 'key': 'bibr11-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/1740774517697919'}, { 'key': 'bibr12-02601060221129144', 'unstructured': 'Physicians RCo. National Early Warning Score (NEWS) 2: Standardising the ' 'assessment of acute-illness severity in the NHS. Updated report of a ' 'working party. London: RCP, 2017. Available at: ' 'https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2.'}, { 'key': 'bibr13-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ajcn/82.5.1090'}, { 'key': 'bibr14-02601060221129144', 'author': 'Said E', 'year': '2020', 'journal-title': 'Journal of Advanced Research'}, { 'key': 'bibr15-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1651-2227.1997.tb14805.x'}, { 'key': 'bibr16-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/sj.ejcn.1601914'}, { 'key': 'bibr17-02601060221129144', 'first-page': '609', 'volume': '73', 'author': 'Sommer A', 'year': '1995', 'journal-title': 'Bulletin of the World Health Organization'}, { 'key': 'bibr18-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1146/annurev.nutr.21.1.167'}, { 'key': 'bibr19-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/0962280215588241'}, { 'key': 'bibr20-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/14651858.CD003700.pub2'}, { 'key': 'bibr21-02601060221129144', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/postgradmedj-2020-137935'}, { 'key': 'bibr22-02601060221129144', 'first-page': '5', 'volume': '68', 'author': 'Zhou W', 'year': '2016', 'journal-title': 'Minerva Pediatrica'}], 'container-title': 'Nutrition and Health', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://journals.sagepub.com/doi/pdf/10.1177/02601060221129144', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://journals.sagepub.com/doi/full-xml/10.1177/02601060221129144', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://journals.sagepub.com/doi/pdf/10.1177/02601060221129144', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 7]], 'date-time': '2022-10-07T08:23:33Z', 'timestamp': 1665131013000}, 'score': 1, 'resource': {'primary': {'URL': 'http://journals.sagepub.com/doi/10.1177/02601060221129144'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 10, 7]]}, 'references-count': 22, 'alternative-id': ['10.1177/02601060221129144'], 'URL': 'http://dx.doi.org/10.1177/02601060221129144', 'relation': {}, 'ISSN': ['0260-1060', '2047-945X'], 'subject': ['Nutrition and Dietetics', 'General Medicine', 'Medicine (miscellaneous)'], 'container-title-short': 'Nutr Health', 'published': {'date-parts': [[2022, 10, 7]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit